Letov 2.5

Letov 2.5



Cadila Healthcare


Zydus Healthcare Phils
Concise Prescribing Info
Adjuvant treatment of postmenopausal women w/ hormone receptor +ve early breast cancer. Extended adjuvant treatment of postmenopausal women w/ early breast cancer who have received prior standard adjuvant tamoxifen therapy. 1st & 2nd line treatment for postmenopausal women hormone-receptor +ve or unknown advanced breast cancer.
Dosage/Direction for Use
Adult & elderly 2.5 mg once daily until tumor progression is evident.
May be taken with or without food.
Special Precautions
Moderate decrease in lymphocyte counts. Thrombocytopenia. Severe impairment of liver function; increase in SGOT, SGPT, γ-glutamyl transpeptidase ≥5x the ULN & bilirubin ≥1.5x the ULN. Pregnancy & lactation. Childn.
Adverse Reactions
Extended adjuvant treatment of early breast cancer: Flushing, asthenia, edema, arthralgia, myalgia, back pain, headache, dizziness, increased sweating, constipation, nausea, diarrhea, hypercholesterolemia, vag hemorrhage, vulvovag dryness, insomnia, dyspnea, infections & infestations & renal disorders. 1st-line breast cancer: Bone/back pain, hot flushes, nausea, arthralgia, dyspnea. Fatigue, chest pain, decreased wt, pain, weakness, hot flushes, lower limb edema, HTN, constipation, diarrhea, vomiting, decreased appetite, abdominal pain, flu, limb pain, headache, insomnia, breast pain, coughing, alopecia/hair thinning, post-mastectomy lymphoedema. 2nd-line breast cancer: Fatigue, chest pain, peripheral edema, asthenia, increased wt, HTN, nausea, vomiting, constipation, diarrhea, abdominal pain, anorexia, dyspepsia, viral infection, hypercholesterolemia, somnolence, dizziness, dyspnea, coughing, hot flushes, rash, pruritus.
ATC Classification
L02BG04 - letrozole ; Belongs to the class of enzyme inhibitors. Used in treatment of neoplastic diseases.
Letov 2.5 FC tab 2.5 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in